Research and Practice in Thrombosis and Haemostasis

Papers
(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach100
How to use and report data on D‐dimer testing in the COVID‐19 era?93
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells79
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing73
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis58
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis53
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)47
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study45
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database42
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients41
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma39
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis39
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic39
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec36
PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina36
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study34
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study34
PB0926 Venous Thromboembolism and Risk of Depression in Patients with Hematological Cancer: A Population-Based Cohort Study33
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study32
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA31
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia31
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS29
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)29
PO16 Hemorrhagic Complications in Patients with Hemophilia A28
PB0612 COVID-19: Predictive Value of Methemoglobinemia28
OC 71.5 Reasons for Anticoagulation Failure and Provider Management28
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro28
OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Pan27
PB1142 A Rapid Centrifugation 4000 g, 4 min Does not Impact Routine Coagulation Assays27
0.16250205039978